Sling Therapeutics Presents Data from Phase 2b/3 LIDS Clinical Trial Demonstrating Durability of Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium

Sling Therapeutics announced efficacy, safety and durability results from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate-to-severe active thyroid eye disease. The results were presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery meeting; the provided article excerpt includes no outcome figures or further details.

Analysis

The investment signal is not the presentation itself but whether the full dataset establishes clinically meaningful durability and a tolerability or administration advantage without sacrificing efficacy. The release excerpt provides no effect sizes, confidence intervals, discontinuations, comparator details, or durability duration, so it does not support repricing the asset or inferring a regulatory path. Any oral-treatment convenience advantage is conditional: it matters commercially only if clinicians and payers see outcomes as competitive with established TED treatment, including Tepezza.

Near term, expect limited read-through absent the underlying data; the company is described as clinical-stage, and the supplied information does not establish an investable ticker. Over 1–3 months, scrutinize the complete conference materials and any company guidance for endpoint consistency, safety, follow-up length, and trial/regulatory next steps. Over 6–18 months, genuinely differentiated durability or tolerability could increase competitive pressure on incumbent treatment access and pricing; a weak or incomplete dataset would leave that threat theoretical. Key reversal risks are loss of effect with longer follow-up, safety signals, or a development plan requiring additional trials. This is a watch item, not a directional trade on the excerpt alone.

Key Decisions for Investors

• Do not trade on the announcement alone: obtain the full LIDS presentation and verify primary endpoint results, statistical uncertainty, adverse-event and discontinuation rates, durability follow-up, and comparator context.
• Set a conditional alert for the incumbent TED-treatment franchise, including Tepezza: revisit exposure only if complete data show durable, competitive outcomes and a credible path to approval; do not infer near-term revenue displacement from an oral formulation claim.
• Track Sling Therapeutics’ next development and regulatory update over the coming 1–3 months. A clear confirmatory-trial or filing path would strengthen the competitive case; additional required studies, safety concerns, or shortened durability would falsify it.
• No options or pair trade is warranted without trial-level data and an identifiable listed security for Sling; reassess only after verifying those inputs and the market’s response.